Inhibrx Biosciences CEO buys 5,895 shares after INBRX-106 trial results
AI Summary
Lappe Mark purchased Inhibrx Biosciences shares after positive INBRX-106 trial results.
The CEO bought 5,895 shares at $99.29 each.
INBRX-106 combined with Keytruda produced a 48.3% tumor response rate.
Inhibrx Biosciences CEO Lappe Mark purchased 5,895 shares at $99.29 each after positive Phase 2 results for INBRX-106 combined with Keytruda. The trial recorded a 48.3% tumor response rate, described as nearly double the rate for Keytruda alone.
The information on this website is generated using AI and we cannot guarantee its accuracy.
Please use it as reference information only.